MYOK MyoKardia Inc.

+0.6  (+1%)
Previous Close 49.39
Open 49.67
Price To Book 3.76
Market Cap 2303064495
Shares 46,070,504
Volume 940,152
Short Ratio
Av. Daily Volume 518,537

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
Mavacamten (MYK-461) - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 interim positive data released March 4, 2019. Data to be presented at ESC August 31-September 4, 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data due 4Q 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
MAD data due 2H 2019.
Heart failure

Latest News

  1. Edited Transcript of MYOK earnings conference call or presentation 9-May-19 8:30pm GMT
  2. MyoKardia, Inc. (MYOK) Q1 2019 Earnings Call Transcript
  3. MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates
  4. MyoKardia: 1Q Earnings Snapshot
  5. MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
  6. MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
  7. MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
  8. Here’s What Hedge Funds Think About MyoKardia, Inc. (MYOK)
  9. Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
  10. Can We See Significant Institutional Ownership On The MyoKardia, Inc. (NASDAQ:MYOK) Share Register?
  11. Detailed Research: Economic Perspectives on TIER REIT, MyoKardia, Radian Group, Packaging Corporation of America, Air Products and Chemicals, and ProAssurance — What Drives Growth in Today's Competitive Landscape
  12. MyoKardia Announces Pricing of Public Offering of Common Stock
  13. The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs
  14. MyoKardia Announces Proposed Public Offering of Common Stock
  15. MyoKardia to Present at Cowen & Co. 39th Annual Health Care Conference
  16. Edited Transcript of MYOK earnings conference call or presentation 4-Mar-19 1:30pm GMT
  17. MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher
  18. MyoKardia stock up 6% after safety-and-efficacy study of HCM treatment shows reduction in symptoms
  19. MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM